INDUSTRY NEWS
ASIMOV PARTNERSHIP WILL ACCELERATE CELL-LINE DEVELOPMENT
Synthetic biology company Asimov, and Lotte Biologics, a global CDMO, have forged a strategic partnership focused on accelerating cell-line development and scaling to GMP manufacturing, having demonstrated a successful scale-up in operations. This collaboration combines
Asimov’s advanced CHO Edge cell line development platform with Lotte Biologics’ large-scale manufacturing services, signifi cantly increasing eff iciency and speed from development to production for therapeutic developers across the world, according to Asimov. Alec Nielsen, Asimov co-founder and CEO, said: “We’re delighted
to be directly integrating with Lotte Biologics’ established manufacturing capabilities, meaning our customers can now transition seamlessly from cell-line development to large-scale GMP production to drastically shorten their development cycles.” James Park, Lotte Biologics CEO,
said: “We believe this agreement will unlock the full potential of both companies’ strengths. By combining Asimov’s impressive technology with Lotte Biologics’ manufacturing excellence, we plan to expland our customer base as well as drive innovation for the biopharmaceutical industry.
Anticipation of the UK’s industrial strategy
SAPIO SCIENCES INTEGRATES PLATFORM INTO INFORMATICS SOLUTION
Lab informatics platform, Sapio Sciences, has integrated Nvidia’s BioNeMe platform into its own solution. This brings AI-driven computational drug discovery directly into the Sapio Electronic Lab Notebook (ELN), helping to streamline workfl ows and improve decision- making in drug discovery. With the BioNeMo platform, researchers can accelerate drug discovery by leveraging science-specifi c AI frameworks, pre-trained models, and generative AI tools to streamline the identifi cation of potential drug candidates and improve target selection accuracy. Nvidia’s BioNeMo provides scientists with a framework
for training and deploying large biomolecular language models at supercomputing scale. The integration of BioNeMo
into the Sapio Platform provides scientists with embedded in silico tools (meaning those performed on a computer), enabling them to, for example, generate novel candidate molecules early in the research process to test their docking with a target protein. With AI-driven molecular simulations available within a single, unifi ed workfl ow, researchers can streamline their processes, enhance innovation, and accelerate the transition from discovery to development.
Following the launch of the UK government’s greenpaper ‘Invest 2035’ and consultation in November last year, the UK’s biotechnology sector is anticipating an industrial strategy and new sector plans focused on growth to be published alongside the government’s spending review in Spring 2025. A statutory, permanent, and independent Industrial Strategy Council will be established with the view that the strategy is informed by a broad and high-quality evidence base. The UK’s BioIndustry Association (BIA) provided a lengthy response at the time, arguing that the strategy should: “Boost existing partnership working structures and policy; ensure focus is maintained on the key sub sectors and technologies in life science; address the key barriers to growth (it lists these in the response); and create the right conditions for increased investment.” The government has said its strategy is unreservedly pro-business, and will engage on complex issues that are barriers to investment including: skills; recruitment of international talent; data; research and development; technology adoption; access to fi nance, competition and regulation. For more on the UK government’s strategy for the sector read Focus: The UK’s bioengineering industry - pages 8 to 12.
www.scientistlive.com 7
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
